Penn Microbiome Therapy for Recurrent Clostridium Difficile Infection
Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This is a randomized, open label, comparative, Phase II study to determine which dose of
fecal microbiota transplant using Penn Microbiome Therapy (PMT) products is most effective in
treating and preventing recurrence of Clostridium difficile infection (C diff).